Concept

NeuroTraq (NTQ) is developing medical technology with a fresh concept for monitoring and managing pain and other neurologic conditions. This concept uniquely combines relatively old and new technologies with a proprietary approach to biometric signal analysis. The result is a new treatment paradigm allowing researchers and clinical practitioners to monitor and manipulate conditions like pain and psychosomatic disorders to a level of efficacy and precision never before achieved.

The unique NTQ concept identifies well defined cardiovascular and neurological biomakers from the complex analysis of multiple biosignal parameters (BAM technoogy).

We are literally one year and two full time software developers from commercial prototypes that can significantly impact cardiovascular and neurological diagnosis and treatment. We are now waiting for an experienced medical executive team to secure NTQ financially and provide the guidance needed to achieve full commercialization.

The ECG is a well known complex bio-signal that quite accurately shows the critical sequences of bioelectrical activity in each heartbeat. The ECG signal is comprised of at least six well known waveform components, and numerous ways have been developed to characterize individual ECG signal components in relation to specific aspects of heart function. About 20 useful parameters can be extracted from the common ECG signal for analysis using current technology.

When a heart has been damaged, the ECG can reflect how it has been affected through numerous parameters. Prior to the onset of major biological damage, the ECG may look fairly normal to most observers. Our current BAM studies are attempting to demonstrate how concurrent multiparameter ECG analysis can identify hidden precursor conditions that lead to potentially damaging CV events. The detection of precursor conditions can allow preemptive treatment before permanent CV damage occurs.

NeuroTraq has prepared a Centers of Excellence (COE) proposal that is ready for submission at the end of February 2010. This proposal addresses a serious issue affecting Chest Pain Centers in all hospital Emergency Centers: despite the impressive procedural refinements that have dramatically improved the survival of heart attack patients, there has been NO significant improvement in the ECG technology that is required to diagnose heart problems. Consequently, 50% of all Chest Pain Center ECGs are non-diagnostic and do not provide the vital information needed to properly assess chest pain patients during the critical first hour of symptoms.

Using analysis tools developed for BAM research, in conjunction with technology licensed from the University of Utah, and in partnership with local and out of state experts, NeuroTraq plans to commercialize a new type of ECG system that can provide orders of magnitude more ECG parametric information in an easy to manipulate and understand format to greatly improve the diagnostic capabilities of Chest Pain Centers clinicians in the critical minutes following the arrival of patients displaying potential cardiovascular symptoms.